Clinical Trial Update: Tislelizumab , Cyclophosphamide, Mitoxantrone Liposomes, Chidamide, and Prednisone in the Treatment of R/R AITL [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating a five-drug regimen (tislelizumab, cyclophosphamide, mitoxantrone liposomes, chidamide, and prednisone) for recurrent or refra…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Angioimmunoblastic T-cell Lymphoma

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Chidamide (chidamide)
• Mitoxantrone liposomes (liposomal mitoxantrone)
• PREDNISONE (Prednisone)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: The Affiliated Hospital of Xuzhou Medical University | Conditions: Angioimmunoblastic T-Cell Lymphoma Recurrent, Angioimmunoblastic T-Cell Lymphoma Refractory | Phase 2 | Status: RECRUITING